Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KPTI NASDAQ:PCRX NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPTIKaryopharm Therapeutics$9.02-4.1%$8.00$3.65▼$10.99$212.21M0.8446,826 shs180,402 shsPCRXPacira BioSciences$23.69-4.4%$23.35$18.80▼$27.64$975.43M0.32593,850 shs532,031 shsTBPHTheravance Biopharma$16.94+1.3%$15.83$8.33▼$21.03$861.84M0.19347,962 shs313,051 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPTIKaryopharm Therapeutics-4.14%+7.38%+42.72%+48.11%+43.86%PCRXPacira BioSciences-4.44%-5.77%+6.38%+16.36%-5.81%TBPHTheravance Biopharma+1.26%+1.62%+5.22%-13.48%+67.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPTIKaryopharm Therapeutics$9.02-4.1%$8.00$3.65▼$10.99$212.21M0.8446,826 shs180,402 shsPCRXPacira BioSciences$23.69-4.4%$23.35$18.80▼$27.64$975.43M0.32593,850 shs532,031 shsTBPHTheravance Biopharma$16.94+1.3%$15.83$8.33▼$21.03$861.84M0.19347,962 shs313,051 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPTIKaryopharm Therapeutics-4.14%+7.38%+42.72%+48.11%+43.86%PCRXPacira BioSciences-4.44%-5.77%+6.38%+16.36%-5.81%TBPHTheravance Biopharma+1.26%+1.62%+5.22%-13.48%+67.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKPTIKaryopharm Therapeutics 2.88Moderate Buy$16.1478.97% UpsidePCRXPacira BioSciences 2.29Hold$29.4024.10% UpsideTBPHTheravance Biopharma 2.75Moderate Buy$21.8328.89% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, TBPH, and KPTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $13.005/1/2026PCRXPacira BioSciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$22.00 ➝ $24.005/1/2026PCRXPacira BioSciences Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.004/27/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.00 ➝ $16.004/10/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)4/7/2026PCRXPacira BioSciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026TBPHTheravance Biopharma B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $17.003/30/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$12.00 ➝ $8.003/26/2026PCRXPacira BioSciences BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$27.00 ➝ $25.003/25/2026KPTIKaryopharm Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $15.003/25/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $8.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKPTIKaryopharm Therapeutics$146.07M1.39N/AN/A($16.00) per share-0.56PCRXPacira BioSciences$726.41M1.28$3.68 per share6.43$16.62 per share1.43TBPHTheravance Biopharma$107.46M8.12N/AN/A$5.86 per share2.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKPTIKaryopharm Therapeutics-$196.04M-$16.62N/AN/AN/A-134.21%N/A-122.29%5/11/2026 (Estimated)PCRXPacira BioSciences$7.03M$0.12197.4310.08N/A0.70%10.24%5.47%N/ATBPHTheravance Biopharma$105.89M$2.038.3467.76N/A98.54%16.76%9.23%5/14/2026 (Estimated)Latest PCRX, TBPH, and KPTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TBPHTheravance Biopharma$0.0280N/AN/AN/A$17.78 millionN/A5/11/2026Q1 2026KPTIKaryopharm Therapeutics-$1.45N/AN/AN/A$31.40 millionN/A4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 million2/26/2026Q4 2025PCRXPacira BioSciences$0.85$0.57-$0.28$0.04$201.93 million$196.87 million2/13/2026Q4 2025KPTIKaryopharm Therapeutics-$2.26-$2.23+$0.03-$5.71$33.16 million$34.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKPTIKaryopharm TherapeuticsN/A1.121.08PCRXPacira BioSciences0.564.733.35TBPHTheravance BiopharmaN/A10.9310.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKPTIKaryopharm Therapeutics66.44%PCRXPacira BioSciences99.73%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipKPTIKaryopharm Therapeutics1.68%PCRXPacira BioSciences6.40%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKPTIKaryopharm Therapeutics38022.55 million22.16 millionOptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionableTBPHTheravance Biopharma11051.51 million47.96 millionOptionablePCRX, TBPH, and KPTI HeadlinesRecent News About These CompaniesTheravance Biopharma (TBPH) Projected to Post Earnings on Thursday3 hours ago | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street ZenMay 2, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 28, 2026 | globenewswire.comLaughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH)April 25, 2026 | insidermonkey.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 25, 2026 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What HappenedApril 23, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance ...April 21, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 21, 2026 | globenewswire.comB. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14April 20, 2026 | insidermonkey.com8 Most Undervalued Biotech Stocks to Buy Right NowApril 18, 2026 | insidermonkey.comTheravance Stock Declines Around 17% in Three Months: Here's WhyApril 16, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 16, 2026 | prnewswire.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockApril 15, 2026 | zacks.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesApril 15, 2026 | prnewswire.comTudor Investment Corp ET AL Sells 145,515 Shares of Theravance Biopharma, Inc. $TBPHApril 15, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 14, 2026 | globenewswire.comZacks Research Has Positive Estimate for TBPH Q1 EarningsApril 14, 2026 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street ZenApril 14, 2026 | marketbeat.comWhat is Zacks Research's Estimate for TBPH Q1 Earnings?April 13, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Theravance Biopharma (TBPH)April 10, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCRX, TBPH, and KPTI Company DescriptionsKaryopharm Therapeutics NASDAQ:KPTI$9.02 -0.39 (-4.14%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$8.97 -0.05 (-0.55%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Pacira BioSciences NASDAQ:PCRX$23.69 -1.10 (-4.44%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$23.70 +0.01 (+0.04%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Theravance Biopharma NASDAQ:TBPH$16.94 +0.21 (+1.26%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$16.86 -0.08 (-0.47%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
